Question 1

What is biotech regulatory submission software?

Accepted Answer

Biotech regulatory submission software is purpose-built for lean biotech teams running INDs through BLAs with limited regulatory headcount. It handles authoring, validation, lifecycle management, and CRO coordination in one platform, replacing the Word + SharePoint + CRO-managed-folders workflow that most early-stage biotechs start with. The case for biotech-specific software (versus general pharma software) is price point, ease of onboarding, and the assumption that the team is small, multi-hatted, and doesn't have dedicated regulatory ops staff.

Question 2

What's the smallest biotech that should use Assyro?

Accepted Answer

A 2-person regulatory team preparing its first IND can productively use Assyro. Below that (one person handling RA, CMC, and clinical ops simultaneously), the platform still works but the leverage is smaller — one person in Word can move faster than one person learning new tooling mid-cycle. The inflection point is typically Series A, around the time the team is scoping the IND filing strategy. Adopting Assyro then vs. adopting it at NDA stage saves the migration cost later.

Question 3

How does Assyro handle CRO-contributed content?

Accepted Answer

CROs get scoped access to the sponsor's workspace for their contributed sections: typically CMC Module 3 if the CRO is running manufacturing, nonclinical Module 4 if running IND-enabling studies, clinical Module 5 if running trials. Access is controlled at section level with audit trail preserved. The sponsor's RA team reviews in-place rather than receiving Word documents via email and manually integrating them. CRO coordination is typically 3-5x faster in this pattern than in a traditional CRO-delivers-documents workflow.

Question 4

Can we use Assyro for FDA pre-IND meetings?

Accepted Answer

Yes. Pre-IND meetings (Type B) are critical for first-time IND sponsors and the briefing document that drives the meeting is the single highest-leverage document a lean biotech writes. Assyro supports the briefing document authoring workflow, captures FDA feedback from the meeting minutes, and links the agreed-upon points into downstream IND content. This matters because FDA will reference the pre-IND agreements throughout the program's lifecycle.

Question 5

What biotech submission types does Assyro support?

Accepted Answer

INDs (original, amendments, safety reports), BLAs (for biologics — standard biotech pathway), Fast Track and Breakthrough designations, Orphan Drug Designation submissions, Regenerative Medicine Advanced Therapy (RMAT) designations, meeting requests (pre-IND, Type B, Type C, EOP2), and post-IND lifecycle events (annual reports, protocol amendments, safety updates). For cell and gene therapy companies, the CBER-specific submission workflows and supplementary documentation are supported.

Question 6

How does Assyro compare to hiring a regulatory consultant?

Accepted Answer

They solve different problems. Consultants bring domain expertise, relationships with FDA, and experience from prior filings. Assyro provides the operating infrastructure — the workspace, the workflow, the audit trail. Most lean biotechs use both: consultants drive strategy and review critical content, Assyro runs the day-to-day execution. Teams that try to replace consultants with software find that they still need judgment; teams that run consulting engagements without infrastructure find the consultant's output doesn't propagate into a sustainable workflow.

Question 7

Is Assyro suitable for rare disease or orphan drug programs?

Accepted Answer

Yes. Orphan Drug Designation and rare disease programs often run with even leaner regulatory teams and tighter budgets. Assyro's coverage of Orphan Drug Designation submissions, OOPD interactions, and the specific considerations for rare disease clinical trial design is strong. The cost point is also meaningful for rare disease programs where every dollar of overhead matters; pricing is designed to be accessible at Series A stage rather than gated to post-IPO companies.

Question 8

What happens during a major funding event or acquisition?

Accepted Answer

Data room exports are one-click. Full submission history, document versions, decision rationale, and audit trail export cleanly for investor or acquirer diligence. Teams using Word-based workflows typically spend 2-4 weeks assembling diligence responses; Assyro users assemble the same response in hours. For biotech specifically, the acquirer or late-stage investor routinely asks to see the regulatory operating model, and a professional audit-ready system is a credibility signal that reduces diligence friction.

Biotech Regulatory Submission Software

Biotech Submission Workflow

File Your First IND Without Hiring a 10-Person RA Team

Coordinate CRO-Generated Content Without Version Chaos

Turn Due-Diligence Prep From Chaos to One-Click Export

Stop Losing Months to 'We'll Fix It In the Next Submission'

Biotech Workflow Controls at Scale

Maintain Audit-Ready Submission Workflows

Manage More Biotech Programs With the Same Team Size

Questions About Biotech Workflows

See Biotech Submission Workflows in Assyro.